Development of combined immunotherapy targeting tumor-infiltrating myeloid cells for oral cancer

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K24088
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Multi-year Fund
• Review Section: 0907:Oral science and related fields
• Research Institution: University of Toyama
• Principal Investigator: Tachinami Hidetake 富山大学, 附属病院, 医員 (30850268)
• Project Period (FY): 2019-08-30 – 2022-03-31
• Keywords: 口腔癌 / 腫瘍免疫 / 免疫チェックポイント阻害剤 / 骨髄抑制性細胞

Outline of Final Research Achievements

In the absence of T cells, myeloid lineage cells have been found to have no effect on cancer growth. T cells do not affect tumor growth in the absence of T cells. Furthermore, TRL3 agonists suppressed tumor growth by altering the properties of myeloid cells. We are currently exploring these phenomena. Clinically, the results showed an association between treatment response and neutrophil/lymphocyte ratio in patients treated with PD-1 immune checkpoint inhibitors.

Free Research Field

口腔癌

Academic Significance and Societal Importance of the Research Achievements

免疫抑制性の骨髄系細胞はT細胞存在下でその抑制効果を示す可能性が示された。以上から、引き続き同抑制性細胞の制御あるいは性質変換（TLR3）についての研究を継続しつつT細胞のアップレギュレーション可能な試薬の探求を図ることは、担癌患者の治療選択肢に大きく影響すると考えている。臨床的には、PD-1免疫チェックポイント阻害剤投与患者の治療効果と好中球・リンパ球比との関連が示された。